Androgen Receptor‐Controlled microRNA‐124‐3p.2 Suppresses Prostate Cancer Progression via CCL2 Inhibition
Cancer Science · 2025
DOI: 10.1111/cas.70157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Shuhei Aoyama und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Hauptthemen laut MEDLINE: MicroRNAs, Receptors, Androgen, Chemokine CCL2, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
We previously reported that androgen receptor (AR) signaling blockade induces chemotactic‐C–C‐motif‐chemokine‐ligand‐2 (CCL2) secretion from prostate cancer cells and activates cancer cells through an autocrine manner. However, the mechanism of how AR negatively regulates CCL2 expression is still unclear. As various microRNAs participate in prostate cancer development, we hypothesized that there are AR‐controlled miRs that regulate CCL2 production. Using LNCaP and C4‐2B cells, miR‐124‐3p.2 was found as a potential miR from the miRNA PCR array and public database. The expression of miR‐124‐3p.2 was inhibited by knockdown AR, and the introduction of miR‐124‐3p.2 mimic decreased CCL2 expression and suppressed cell migration. Dihydrotestosterone led to miR‐124‐3p.2 upregulation and CCL2 downregulation. To examine whether miR‐124‐3p.2 and CCL2 are involved in prostate cancer progression, their expression levels and clinical parameters were analyzed using prostate biopsy samples and whole blood RNAs obtained from the biopsied patients. Patients with low miR‐124‐3p.2 and high CCL2 levels showed a shorter time to castration‐resistant prostate cancer development than those with high miR‐124‐3p.2 and low CCL2 levels. Our study demonstrated that AR suppresses CCL2 expression via miR‐124‐3p.2, and the miR‐124‐3p.2‐CCL2 axis may be a novel therapeutic target and a useful blood prognostic biomarker for advanced prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
- Department of Clinical Engineering, Faculty of Health Sciences, Komatsu University, Komatsu, Japan.
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Science, Kanazawa University, Kanazawa, Japan.
- Immunology Research Center, National Health Research Institutes, Zhunan, Taiwan.
ORCID-Profile: Kouji Izumi, Ryunosuke Nakagawa, Ren Toriumi, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Hiroaki Iwamoto, Hiroshi Yaegashi, Shohei Kawaguchi
Förderung
- JSPS KAKENHI
Zitieren
APA
Aoyama, S., Izumi, K., Hiratsuka, K., Inaba, T., Koketsu, Y., Nakagawa, R., Toriumi, R., Kamijima, T., Kano, H., Makino, T., Naito, R., Kadomoto, S., Iwamoto, H., Yaegashi, H., Kawaguchi, S., Shigehara, K., Nohara, T., Nakata, H., Saito, Y., …, & Mizokami, A. (2025). Androgen Receptor‐Controlled microRNA‐124‐3p.2 Suppresses Prostate Cancer Progression via CCL2 Inhibition. Cancer Science. https://doi.org/10.1111/cas.70157
Vancouver
Aoyama S, Izumi K, Hiratsuka K, Inaba T, Koketsu Y, Nakagawa R, et al. Androgen Receptor‐Controlled microRNA‐124‐3p.2 Suppresses Prostate Cancer Progression via CCL2 Inhibition. Cancer Science. 2025. doi:10.1111/cas.70157
BibTeX
@article{Aoyama2025,
author = {Aoyama, Shuhei and Izumi, Kouji and Hiratsuka, Kaoru and Inaba, Takahiro and Koketsu, Yoshiki and Nakagawa, Ryunosuke and Toriumi, Ren and Kamijima, Taiki and Kano, Hiroshi and Makino, Tomoyuki and Naito, Renato and Kadomoto, Suguru and Iwamoto, Hiroaki and Yaegashi, Hiroshi and Kawaguchi, Shohei and Shigehara, Kazuyoshi and Nohara, Takahiro and Nakata, Hiroki and Saito, Yohei and Nakagawa-Goto, Kyoko and Lin, Wen-Jye and Mizokami, Atsushi},
title = {Androgen Receptor‐Controlled microRNA‐124‐3p.2 Suppresses Prostate Cancer Progression via CCL2 Inhibition},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70157}
}
EUVIMED